A detailed history of Financial Perspectives, Inc transactions in Genmab A/S stock. As of the latest transaction made, Financial Perspectives, Inc holds 1,333 shares of GMAB stock, worth $27,286. This represents 0.01% of its overall portfolio holdings.

Number of Shares
1,333
Previous 1,333 -0.0%
Holding current value
$27,286
Previous $33.5 Million 2.98%
% of portfolio
0.01%
Previous 0.01%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Jan 09, 2024

SELL
$41.55 - $48.72 $65,067 - $76,295
-1,566 Reduced 54.02%
1,333 $58.3 Million
Q2 2021

Jan 09, 2024

SELL
$32.88 - $44.57 $3.03 Million - $4.11 Million
-92,275 Reduced 96.95%
2,899 $118 Million
Q1 2021

Jan 09, 2024

BUY
$30.92 - $44.4 $2.85 Million - $4.1 Million
92,275 Added 3182.99%
95,174 $2.9 Million
Q3 2020

Jan 09, 2024

BUY
$33.07 - $38.68 $95,869 - $112,133
2,899 New
2,899 $106 Million

Others Institutions Holding GMAB

About GENMAB A/S


  • Ticker GMAB
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 658,292,992
  • Market Cap $13.5B
  • Description
  • Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...
More about GMAB
Track This Portfolio

Track Financial Perspectives, Inc Portfolio

Follow Financial Perspectives, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Financial Perspectives, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Financial Perspectives, Inc with notifications on news.